AIDS.GOV | SERVICE LOCATOR | SEARCH

BLOG.AIDS.GOV

MENU

HIV Policy & Programs

Looking Ahead to 2015

ron_video

As 2014 comes to a close and we prepare to celebrate the potential of the new year, Dr. Ronald Valdiserri, Deputy Assistant Secretary for Health, Infectious Diseases, shares his thoughts on the year ahead in this video message. Dr. Valdiserri, who leads efforts to implement the National HIV/AIDS Strategy and the Viral Hepatitis Action Plan,…

2014 Viral Hepatitis Year-in-Review and Looking to 2015

Ronald Valdiserri

2014 has been a year of both opportunities and challenges in the fight against viral hepatitis. In May, the World Health Assembly passed a new resolution  [PDF 151 KB] on viral hepatitis, urging member states to develop and implement coordinated, national strategies for preventing, diagnosing and treating viral hepatitis.  Our nation’s own comprehensive viral hepatitis strategy,…

FDA Commissioner Margaret A. Hamburg’s statement on FDA’s blood donor deferral policy for men who have sex with men

FDA

The U.S. Food and Drug Administration is a science-based regulatory agency that works to protect and promote the public health. In this role, it is our responsibility to regulate the blood supply and to help ensure its continued safety for the patients who receive these life-saving products. Over the past several years, in collaboration with…

Douglas Brooks: World AIDS Day & New Year’s Reflection

Listen:

Javascript and flash are required to play this audio file.

Download MP3
Douglas Brooks

As 2014 draws to a close, we sat down with Douglas Brooks, Director of the White House Office of National AIDS Policy (ONAP), to talk about his reflections on the White House’s World AIDS Day 2014 event and his thoughts about the work ahead in 2015 to move closer to an AIDS-free generation. In his review…

FDA approves Viekira Pak to treat hepatitis C

FDA

The U.S. Food and Drug Administration today approved Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets) to treat patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with a type of advanced liver disease called cirrhosis. Hepatitis C is a viral disease that causes inflammation of the liver that…

Black Voices: HIV from a Friend’s Perspective

Anthony Roberts, Jr.

As an HIV-negative, black, gay male, I can’t pretend to know the feelings and emotions that come with discovering that you are HIV-positive. However, what I do know is that I have chosen to use my skills in marketing and communications to inform, influence, advocate, and serve as an ally for individuals near and far…

Two New Hepatitis C Resources Support Expanding Provider Capacity

Ronald Valdiserri

Two professional medical societies have recently launched initiatives to support a wider variety of health care providers in adapting to new roles and opportunities resulting from the rapidly evolving arena of hepatitis C (HCV) screening, diagnosis, and treatment. As the Viral Hepatitis Action Plan observes, providers at every level in the healthcare system can play…

The 2014 Liver Meeting – Report on Viral Hepatitis Coverage at the American Association for the Study of Liver Diseases (AASLD) Meeting

Capture

Last month, the American Association for the Study of Liver Diseases (AASLD) annual meeting  (The Liver Meeting®) took place, convening nearly 10,000 physicians, surgeons, researchers, allied health professionals and advocates from around the world to discuss the natural history, prevention, and cure of liver diseases. With the availability of new all-oral, direct-acting agents (DAAs), there…